Advertisement

Port-Wine Birthmark and Hemangioma

  • Leah K. Spring
  • Andrew C. KrakowskiEmail author
Chapter

Abstract

Port-wine birthmarks (PWB) and infantile hemangiomas (IH) typically present, respectively, at birth to within weeks of birth and represent two of the most common types of vascular anomalies in children. Without treatment, port-wine birthmarks follow an expected evolution of hypertrophic change and bleb development (usually around the third decade of life) with associated physical and psychosocial comorbidities. Conversely, infantile hemangiomas typically follow a process of predictable involution that begins at approximately 1 year of life; despite the overall positive clinical outcome of most infantile hemangiomas, permanent sequelae such as telangiectasia, atrophic wrinkling, and redundant skin with fibro-fatty residua may be observed in up to 50% of patients after “spontaneous resolution,” a consideration that should be included in long-term prognosis and patient expectation discussions. Myriad medical and procedural treatment options exist for both PWB and IH and their associated complications, and patients may seek intervention at any age (i.e., infant to adult). It is therefore incumbent on all dermatologists and plastic surgeons to keep abreast of evolving treatment technologies and therapeutic approaches in order to deliver optimal clinical outcomes. This chapter reviews the published evidence regarding clinical evaluation and efficacy of available procedural interventions for PWB and IH and offers a practical approach based on that data.

Keywords

Port-wine birthmarks Port-wine stain Hemangioma Laser Pulsed dye PDL Nd:YAG Alexandrite 

References

  1. 1.
    Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies. Pediatrics. 2015;136(1):e203–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Waelchli R, Aylett S, Robinson K, Chong W, Martinez A, Kinsler V. New vascular classification of port-wine stains: improving prediction of Sturge–Weber risk. Br J Dermatol. 2014;171(4):861–7.  https://doi.org/10.1111/bjd.13203.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368(21):1971–9.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Dutkiewicz AS, Ezzedine K, Mazereeuw-Hautier J, et al. A prospective study of risk for Sturge-Weber syndrome in children with upper facial port-wine stain. J Am Acad Dermatol. 2015;72(3):473–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Van Drooge AM, Beek JF, van der Veen JP, et al. Hypertrophy in port-wine stains: prevalence and patient characteristics in a large patient cohort. J Am Acad Dermatol. 2012;67(2):1214–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee JW, Chung HY, Cerrati EW, TM O, Waner M. The natural history of soft tissue hypertrophy, bony hypertrophy, and nodule formation in patients with untreated head and neck capillary malformations. Dermatol Surg. 2015;41(11):1241–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Passeron T, Salhi A, Mazer JM, et al. Prognosis and response to laser treatment of early-onset hypertrophic post-wine stains (PWS). J Am Acad Dermatol. 2016;75(1):64–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Minkis K, Geronemus RG, Hale EK. Port wine stain progression: a potential consequence of delayed and inadequate treatment? Lasers Surg Med. 2009;41(6):423–6.  https://doi.org/10.1002/lsm.20788.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Kanada KN, Merin MR, Munden A, Friedlander SF. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr. 2012;161(2):240–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Goelz R, Poets CF. Incidence and treatment of infantile haemangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2015;100(1):F85–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol. 2002;138(12):1567–76.CrossRefPubMedGoogle Scholar
  13. 13.
    Frieden IJ, Reese V, Cohen D. PHACE syndrome: the association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol. 1996;132(3):307–11.CrossRefPubMedGoogle Scholar
  14. 14.
    Metry D, Heyer G, Hess C, et al. PHACE syndrome research conference. Consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics. 2009;124(5):1447–56.CrossRefPubMedGoogle Scholar
  15. 15.
    Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010;157(5):795–801, e791.CrossRefPubMedGoogle Scholar
  16. 16.
    Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a “beard” distribution. J Pediatr. 1997;131(4):643–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Garzon MC. Infantile hemangiomas. In: Bolognia JL, Jorizzo JL, Rapini RP, editors. Dermatology. London: Mosby; 2003. p. 1599–614.Google Scholar
  18. 18.
    Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents’ photographs tell us. Pediatrics. 2012;130(2):e314–20.CrossRefPubMedGoogle Scholar
  19. 19.
    Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–40.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zheng JW, Zhang L, Zhou Q, et al. A practical guide to treatment of infantile hemangiomas of the head and neck. Int J Clin Exp Med. 2013;6(10):851–60.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Nguyen TA, Krakowski AC, Naheedy JH, Kruk PG, Friedlander SF. Imaging pediatric vascular lesions. J Clin Aesthetic Dermatol. 2015;8(12):27–41.Google Scholar
  22. 22.
    Gressens P, Hüppi PS. Are prenatal ultrasounds safe for the developing brain? Pediatr Res. 2007;61:265–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Greenspan A, McGahan JP, Vogelsang P, Szabo RM. Imaging strategies in the evaluation of soft-tissue hemangiomas of the extremities: correlation of the findings of plain radiography. Angiography, CT, MRI, and ultrasonography in 12 histologically proven cases. Skelet Radiol. 1992;21:11–8.CrossRefGoogle Scholar
  24. 24.
    Kanal E, Borgstede JP, Barkovich AJ, et al. American College of Radiology white paper on MR safety. AJR Am J Roentgenol. 2002;178:1335–47.CrossRefPubMedGoogle Scholar
  25. 25.
    Kanal E, Borgstede JP, Barkovich AJ, et al. American College of Radiology white paper on MR safety: 2004 update and revisions. AJR Am J Roentgenol. 2004;182:1111–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Khaier A, Nischal KK, Espinosa M, Manoj B. Periocular port wine stain: the great Ormond street hospital experience. Ophthalmology. 2011;118(11):2274–8, e2271.CrossRefPubMedGoogle Scholar
  27. 27.
    Tallman B, Tan OI, Morelli JG, et al. Location of port-wine stains and the likelihood of ophthalmic and/or central nervous system complications. Pediatrics. 1991;87(3):323–7.PubMedGoogle Scholar
  28. 28.
    Izikson L, Nelson JS, Anderson RR. Treatment of hypertrophic and resistant port wine stains with a 755 nm laser: a case series of 20 patients. Lasers Surg Med. 2009;41(6):427–32.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lister T, Wright P, Chappell P. Spectrophotometers for the clinical assessment of port-wine stain skin lesions: a review. Lasers Med Sci. 2010;25(3):449–57.CrossRefPubMedGoogle Scholar
  30. 30.
    Jung B, Choi B, Durkin AJ, Kelly KM, Nelson JS. Characterization of port wine stain skin erythema and melanin content using cross-polarized diffuse reflectance imaging. Lasers Surg Med. 2004;34(2):174–81.CrossRefPubMedGoogle Scholar
  31. 31.
    Kim CS, Kim MK, Jung B, Choi B, Verkruysse W, Jeong MY, Nelson JS. Determination of an optimized conversion matrix for device independent skin color image analysis. Lasers Surg Med. 2005;37(2):138–43.CrossRefPubMedGoogle Scholar
  32. 32.
    Sharif SA, Taydas E, Mazhar A, et al. Noninvasive clinical assessment of port-wine stain birthmarks using current and future optical imaging technology: a review. Br J Dermatol. 2012;167(6):1215–23.  https://doi.org/10.1111/j.1365-2133.2012.11139.x.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983;220:524–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Smit JM, Bauland CG, Wijnberg DS, Spauwen PH. Pulsed dye laser treatment, a review of indications and outcome based on published trials. Br J Plast Surg. 2005;58(7):981–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Faurschou A, Olesen AB, Leonardi-Bee J, Haedersdal M. Lasers or light sources for treating port-wine stains. Cochrane Database Syst Rev. 2011;(11):CD007152.Google Scholar
  36. 36.
    Yung A, Sheehan-Dare R. A comparative study of a 595-nm with a 585-nm pulsed dye laser in refractory port wine stains. Br J Dermatol. 2005;153(3):601–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Greve B, Raulin C. Prospective study of port wine stain treatment with dye laser, comparison of two wavelengths (585 nm vs 595 nm) and two pulsed durations (0.5 milliseconds vs 20 milliseconds). Laser Surg Med. 2004;34(2):168–73.CrossRefGoogle Scholar
  38. 38.
    Sakamoto FJ, Avram MM, Anderson RR. Lasers and other energy technologies—principles & skin interactions. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. Philadelphia: Elsevier; 2012. p. 2255.Google Scholar
  39. 39.
    Yu W, Ying H, Chen Y, et al. In vivo investigation of the safety and efficacy of pulsed dye laser with two spot sizes in port-wine stain treatment: a prospective side-by-side comparison. Photomed Laser Surf. 2017;35(9):465–71.CrossRefGoogle Scholar
  40. 40.
    Wanner M, Sakamoto FJ, Avram MM, et al. Immediate skin responses to laser and light treatments: therapeutic endpoints: how to obtain efficacy. J Am Acad Dermatol. 2016 May;74(5):821–33.CrossRefPubMedGoogle Scholar
  41. 41.
    Brauer JA, Farhadian JA, Bernstein LJ, Bae YS, Geronemus RG. Pulsed dye laser at subpurpuric settings for the treatment of pulsed dye laserinduced ecchymoses in patients with port-wine stains. Dermatol Surg. 2018;44(2):220–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Chapas AM, Eickhorst K, Geronemus RG. Efficacy of early treatment of facial port wine stains in newborns: a review of 49 cases. Lasers Surg Med. 2007;39(7):563–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Chapas AM, Geronemus RG. Physiologic changes in vascular birthmarks during early infancy: mechanisms and clinical implications. J Am Acad Dermatol. 2009;61(6):1081–2.CrossRefPubMedGoogle Scholar
  44. 44.
    Reyes BA, Geronemus R. Treatment of port-wine stains during childhood with the flash lamp pumped pulsed dye laser. J Am Acad Dermatol. 1990;23:1142–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Fitzpatrick RE, Lowe NJ, Goldman NP, Borden H, Behr KL, Ruiz-Esparza J. Flashlamp-pumped pulsed dye laser treatment of port-wine stains. J Dermatol Surg Oncol. 1994;20:743–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Cordoro KM, Speetzen LS, Koerper MA, IJ F. Physiologic changes in vascular birthmarks during early infancy: mechanisms and clinical implications. J Am Acad Dermatol. 2009;60:669–75.CrossRefPubMedGoogle Scholar
  47. 47.
    Renfro L, Geronemus RG. Anatomical differences of port-wine stains in response to treatment with the pulsed dye laser. Arch Dermatol. 1993;129(2):182–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Yu W, Ma G, Qiu Y, et al. Why do port-wine stains (PWS) on the lateral face respond better to pulsed dye laser (PDL) than those located on the central face? J Am Acad Dermatol. 2016;74(3):527–35.CrossRefPubMedGoogle Scholar
  49. 49.
    Chen JK, Ghasri P, Aguilar G, et al. An overview of clinical and experimental treatment modalities for port wine stains. J Am Acad Dermatol. 2012;67(2):289–304.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Mork NJ, Austad J, Helsing P. Do port wine stains recur after successful treatment with pulsed dye laser? J Eur Acad Dermatol Venereol. 1998;11:S142–3.CrossRefGoogle Scholar
  51. 51.
    Michel S, Landthaler M, Hohenleutner U. Recurrence of port-wine stains after treatment with the flash lamp pumped pulsed dye laser. Br J Dermatol. 2000;143:1230–4.CrossRefPubMedGoogle Scholar
  52. 52.
    Orten SS, Waner M, Flock S. Port wine stains: an assessment of 5 years of treatment. Arch Otolaryngol Head Neck Surg. 1996;122:1174–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Yang MU, Yaroslavsky AN, Farinelli WA, et al. Long-pulsed neodymium;yttrium-aluminum-garnet laser treatment for port-wine stains. J Am Acad Dermatol. 2005;52(3 Pt1):480–90.CrossRefPubMedGoogle Scholar
  54. 54.
    Izikson L, Nelson JS, Anderson RR. Treatment of hypertrophic and resistant port wine stains with a 755 nm laser: a case series of 20 patients. Lasers Surg Med. 2009;41(6):427–32.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Reddy KK, Brauer JA, Idriss MH, et al. Treatment of port-wine stains with a short pulse width 532-nm Nd:YAG laser. J Drugs Dermatol. 2013 Jan;12(1):66–71.PubMedGoogle Scholar
  56. 56.
    McGill DJ, MacLaren W, Mackay IR. A direct comparison of pulsed dye, alexandrite, KTP and Nd:YAG lasers and IPL in patients with previously treated capillary malformations. Lasers Surg Med. 2008;40(6):390–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Li L, Kono T, Groff WF, et al. Comparison study of a long-pulse pulsed dye laser and a long-pulse pulsed alexndrite laser in the treatment of port wine stains. J Cosmet Laser Ther. 2008;10(1):12–5.CrossRefPubMedGoogle Scholar
  58. 58.
    Tierney EP, Hanke CW. Alexandrite laser for the treatment of port wine stains refractory to pulsed dye laser. Dermatol Surg. 2011;37(9):1268–78.CrossRefPubMedGoogle Scholar
  59. 59.
    Grillo E, Gonzalez-Munoz P, Boixeda P, et al. Alexandrite laser for the treatment of resistant and hypertrophic port wine stains: a clinical, histological and histochemical study. Actas Dermosifiliogr. 2016;107(7):591–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Carlsen BC, Wenande E, Erlendsson AM, Faurschou A, Dierickx C, Haedersdal M. A randomized side-by-side study comparing alexandrite laser at different pulse durations for port wine stains. Lasers Surg Med. 2017;49(1):97–103.CrossRefPubMedGoogle Scholar
  61. 61.
    Li D, Chen B, Wu W, Ying Z. Experimental investigation on the vascular thermal response to near-infrared laser pulses. Lasers Med Sci. 2017;32(9):2023–38. Epub ahead of print.CrossRefPubMedGoogle Scholar
  62. 62.
    Van Drooge AM, Bosveld B, van der Veen JP, et al. Long-pulsed 1064 nm Nd:YAG laser improves hypertrophic port-wine stains. J Eur Acad Dermatol Venereol. 2013;27(11):1381–6.CrossRefPubMedGoogle Scholar
  63. 63.
    Kono T, Frederick Groff W, Chan HH, et al. Long-pulsed neodymium:yttrium-aluminum-garnet laser treatment for hypertrophic port-wine stains on the lips. J Cosmet Laser Ther. 2009;11(1):11–3.CrossRefPubMedGoogle Scholar
  64. 64.
    Chang HS, Kim YG, Lee JH. Treatment using a long pulsed nd:yag laser with a pulsed dye laser for four cases of blebbed pot wine stains. Ann Dermatol. 2011;23(Suppl 1):S75–8.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Alster TS, Tanzi EL. Combined 595-nm and 1064-nm laser irradiation of recalcitrant and hypertrophic port-wine stains in children and adults. Dermatol Surg. 2009;35(6):914–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Wang T, Chen D, Yang J, Ma G, Yu W, Lin X. Safety and efficacy of dual wavelength laser (1064 nm + 595 nm) for treatment of non-treated portwine stains. J Eur Acad Dermatol Venereol. 2018;32(2):260–4. Epub ahead of print.CrossRefPubMedGoogle Scholar
  67. 67.
    Borges da Costa J, Boxixeda P, Moreno C, Santiago J. Treatment of resistant port-wine stains with a pulsed dual wavelength 595 and 1064 nm laser: a histochemical evaluation of the vessel wall destruction and selectivity. Photomed Laser Surg. 2009;27(4):599–605.CrossRefPubMedGoogle Scholar
  68. 68.
    Al-Dhalimi MA, Al-Janabi MH. Split lesion randomized comparative study between long pulsed Nd:YAG laser 532 and 1064 nm in treatment of facial port-wine stain. Lasers Surg Med. 2016;48(9):852–8.CrossRefPubMedGoogle Scholar
  69. 69.
    Kwiek B, Rozalski M, Kowalewski C, Ambroziak M. Retrospective single center study of the efficacy of large spot 532 nm laser for the treatment of facial capillary malformations in 44 patients with the use of three-dimensional image analysis. Lasers Surg Med. 2017;49(8):743–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Al-Janabi MH, Ismaeel Ali NT, Mohamed Al-Sabti KD, et al. A new imaging technique for assessment of the effectiveness of long pulse Nd:YAG 532 nm laser in treatment of facial port wine stain. J Cosmet Laser Ther. 2017;28:1–4. Epub ahead of print.Google Scholar
  71. 71.
    Latkowski IT, Wysocki MS, Siewiera IP. Own clinical experience in treatment of port-wine stain with KTP 532 nm laser. Wiad Lek. 2005;58(7–8):391–6. Article in Polish.PubMedGoogle Scholar
  72. 72.
    Pence B, Aybey B, Ergenekon G. Outcomes of 532 nm frequency-doubled Nd:YAG laser use in the treatment of port-wine stains. Dermatol Surg. 2005;31(5):509–17.CrossRefPubMedGoogle Scholar
  73. 73.
    Ho WS, Chan HH, Ying SY, Chan PC. Laser treatment of congenital facial port-wine stains: long-term efficacy and complication in Chinese patients. Lasers Surg Med. 2002;30(1):44–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Shi W, Wang J, Lin Y, et al. Treatment of port wine stains with pulsed dye laser: a retrospective study of 848 cases in Shandong Province, People’s Republic of China. Drug Des Devel Ther. 2014;8:2531–8.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Liu H, Dang Y, Chai X, Wang Z, Ma L, Ren Q. Treatment of port-wine stains with the 595-nm pulsed dye laser: a pilot study in Chinese patients. Clin Exp Dermatol. 2007;32(6):646–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Sharma VK, Khandpur S. Efficacy of pulsed dye laser in facial port-wine stains in Indian patients. Dermatol Surg. 2007;33(5):560–6.PubMedGoogle Scholar
  77. 77.
    Khandpur S, Sharma VK. Assessment of efficacy of the 595-nm pulsed dye laser in the treatment of facial port-wine stains in Indian patients. Dermatol Surg. 2016;42(6):717–26.CrossRefPubMedGoogle Scholar
  78. 78.
    Thajudheen CP, Jyothy K, Priyadarshini A. Treatment of port-wine stains with flash lamp pumped pulsed dye laser on Indian skin: a six year study. J Cutan Aesthet Surg. 2014;7(1):32–6.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Bae YS, Ng E, Geronemus RG. Successful treatment of two pediatric port wine stains in darker skin types using 595 nm laser. Laser Surg Med. 2016;48(4):339–42.CrossRefGoogle Scholar
  80. 80.
    Woo SH, Ahn HH, Kim SN, Kye YC. Treatment of vascular skin lesions with the variable-pulsed 595 nm pulsed dye laser. Dermatol Surg. 2006;32(1):41–8.CrossRefPubMedGoogle Scholar
  81. 81.
    Moy WJ, Ma G, Kelly KM, Choi B. Hemoporfin-mediated photodynamic therapy on normal vasculature: implications for phototherapy on port-wine stain birthmarks. J Clin Translat Res. 2016;2(30):107–11.Google Scholar
  82. 82.
    Gu Y, Huang NY, Liang J, Pan YM, Liu FG. Clinical study of 1949 cases of port wine stains treated with vascular photody- namic therapy (Gu’s pdt). Ann Dermatol Venereol. 2007;134:241–4.CrossRefPubMedGoogle Scholar
  83. 83.
    Xiao Q, Li Q, Yuan KH, Cheng B. Photodynamic therapy of port-wine stains: long-term efficacy and complication in Chinese patients: photodynamic therapy of port-wine stains. J Dermatol. 2011;38:1146–52.CrossRefPubMedGoogle Scholar
  84. 84.
    Qin ZP, Li KL, Ren L, Liu XJ. Photodynamic therapy of port wine stains-a report of 238 cases. Photodiagn Photodyn Ther. 2007;4:53–9.CrossRefGoogle Scholar
  85. 85.
    Zhao Y, Zhou Z, Zhou G, et al. Efficacy and safety of hemoporfin in photodynamic therapy for port-wine stain: a multicenter and open-labeled phase IIa study. Photodermatol Photoimmunol Photomed. 2011;27:17–23.CrossRefPubMedGoogle Scholar
  86. 86.
    Tang Y, Xie H, Li J, Jian D. The association between treatment reactions and treatment efficiency of Hemoporfin-photodynamic therapy on port wine stains: a prospective double blinded randomized controlled trial. Photodiagn Photodyn Ther. 2017;18:171–8.CrossRefGoogle Scholar
  87. 87.
    Kelly KM. Current treatment options for port wine stain birthmarks. Photodiagn Photodyn Ther. 2007;4(3):147–8.CrossRefGoogle Scholar
  88. 88.
    Admani S, Krakowski AC, Nelson JS. Beneficial effects of early pulsed dye laser therapy in individuals with infantile hemangiomas. Dermatol Surg. 2012;38:1732–8.CrossRefPubMedGoogle Scholar
  89. 89.
    Chinnadurai S, Sathe NA, Surawicz T. Laser treatment of infantile hemangioma: a systematic review. Lasers Surg Med. 2016;48(3):221–33.CrossRefPubMedGoogle Scholar
  90. 90.
    Kwon SH, Choi JW, Byun SY, et al. Effect of early long-pulsed pulsed dye laser treatment in infantile hemagniomas. Dermatol Surg. 2014;40:405–11.Google Scholar
  91. 91.
    Chen W, Yang C, Liu S, Yang S. Curative effect study of pulsed dye laser in the treatment of 43 patients with hand infantile hemangioma. Eur J Dermatol. 2014;24(1):76–9.PubMedGoogle Scholar
  92. 92.
    Kaune KM, Lauerer P, Kietz S, et al. Combination therapy of infantile hemangiomas with pulsed dye laser and Nd:YAG laser is effective and safe. J Dtsch Dermatol Ges. 2014;12(6):473–8.PubMedGoogle Scholar
  93. 93.
    Zhong SX, Tao YC, Zhou JF, Liu YY, Yao L, Li SS. Infantile hemangioma: clinical characteristics and efficacy of treatment with the long-pulsed 1064 nm neodymium-doped yttrium aluminum garnet laser in 794 Chinese patients. Pediatr Dermatol. 2015;32(4):495–500.CrossRefPubMedGoogle Scholar
  94. 94.
    Batta K, Goodyear HM, Moss C, Williams HC, Hiller L, Waters R. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Lancet. 2002;360:521–7.CrossRefPubMedGoogle Scholar
  95. 95.
    David LR, Malek MM, Argenta LC. Efficacy of pulse dye laser therapy for the treatment of ulcerated haemangiomas: a review of 78 patients. Br J Plast Surg. 2003;56(4):317–27.CrossRefPubMedGoogle Scholar
  96. 96.
    Cerrati EW, TM O, Chung H, Waner M. Diode laser for the treatment of telangiectasias following hemangioma involution. Otolaryngol Head Neck Surg. 2015;152(2):239–43.CrossRefPubMedGoogle Scholar
  97. 97.
    Alcántara González J, Boixeda P, Truchuelo Díez MT, López Gutiérrez JC, Olasolo PJ. Ablative fractional yttrium-scandium-gallium-garnet laser for scarring residual haemangiomas and scars secondary to their surgical treatment. J Eur Acad Dermatol Venereol. 2012;26(4):477–82.CrossRefPubMedGoogle Scholar
  98. 98.
    Brightman LA, Brauer JA, Terushkin V, Hunzeker C, Reddy KK, Weiss ET, Karen JK, Hale EK, Anolik R, Bernstein L, Geronemus RG. Ablative fractional resurfacing for involuted hemangioma residuum. Arch Dermatol. 2012;148(11):1294–8.CrossRefPubMedGoogle Scholar
  99. 99.
    Feng H, Kauvar AN. Successful treatment of a residual, thick, infantile Hemangioma in a darker phototype pediatric patient using the 755 nm long-pulsed alexandrite laser. Dermatol Surg. 2017;43:1514–6.CrossRefPubMedGoogle Scholar
  100. 100.
    Daramola OO, Chun RH, Nash JJ, Drolet BA, North PE, Jensen JN, Kerschner JE. Surgical treatment of infantile hemangioma in a multidisciplinary vascular anomalies clinic. Int J Pediatr Otorhinolaryngol. 2011;75(10):1271–4.CrossRefPubMedGoogle Scholar
  101. 101.
    Emir S, Gürlek Gökçebay D, Demirel F, Tunç B. Efficacy and safety of intralesional corticosteroid application for hemangiomas. Arch Dis Child. 2011;96(6):587–9.CrossRefGoogle Scholar
  102. 102.
    Morkane C, Gregory JW, Watts P, Warner JT. Adrenal suppression following intralesional corticosteroids for periocular haemangiomas. Turk J Med Sci. 2015;45(2):335–8.Google Scholar
  103. 103.
    Qiu Y, Lin X, Ma G, Chang L, Jin Y, Chen H, Hu X. Eighteen cases of soft tissue atrophy after intralesional bleomycin A5 injections for the treatment of infantile hemangiomas: a long-term follow-up. Pediatr Dermatol. 2015;32(2):188–91.CrossRefPubMedGoogle Scholar
  104. 104.
    Torres-Pradilla M, Baselga E. Failures of intralesional propranolol in infaile hemangiomas. Pediatr Dermatol. 2014;31(2):156–8.CrossRefPubMedGoogle Scholar
  105. 105.
    Ma G, Wu P, Lin X, et al. Fractional carbon dioxide laser-assisted drug delivery of topical timolol solution for the treatment of deep infantile hemangioma: a pilot study. Ped Dermatol. 2014;31(3):386–91.CrossRefGoogle Scholar
  106. 106.
    Reischle S, Schuller-Petrovic S. Treatment of capillary hemangiomas of early childhood with a new method of cryosurgery. J Am Acad Dermatol. 2000;42:809–13.CrossRefPubMedGoogle Scholar
  107. 107.
    Brightman LA, Geronemus RG, Reddy KK. Laser treatment of port-wine stains. Clin Cosmet Investig Dermatol. 2015;8:27–33.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Ortiz AE, Ross EV. A complication of an eyelid hemangioma treated with a long-pulsed 1064 nm Nd:YAG laser. Lasers Surg Med. 2010;42(10):736–7.CrossRefPubMedGoogle Scholar
  109. 109.
    Reyes BA, Geronemus R. Treatment of port-wine stains during childhood with the flashlamp-pulsed pulsed dye laser. J Am Acad Dermatol. 1990;23:1142–8.CrossRefPubMedGoogle Scholar
  110. 110.
    Hzura GJ, Geronemus RG, Dover JS, Arndt KA. Lasers in dermatology—1003. Arch Dermatol. 1993;129:1026–35.CrossRefGoogle Scholar
  111. 111.
    Cattano D, Young C, Straiko MM, Olney JW. Subanesthetic doses of propofol induce neuroapoptosis in the infant mouse brain. Anesth Analg. 2008;106:1712–4.CrossRefPubMedGoogle Scholar
  112. 112.
    Jevtovic-Todorovic V, Hartman RE, Izumi Y, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci. 2003;23:876–82.CrossRefGoogle Scholar
  113. 113.
    Rizzi S, Ori C, Jevtovic-Todorovic V. Timing versus duration: determinants of anesthesia-induced developmental apoptosis in the young mammalian brain. Ann N Y Acad Sci. 2010;1199:43–51.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Sun LS, Li G, Miller TL, et al. Association between a single general anesthesia exposure before age 36 montsh and neurocognitive outcomes in later childhood. JAMA. 2016;315(21):2312–20.CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Glatz P, Sandin RH, Pedersen NL, et al. Association of anesthesia and surgery during childhood with long-term academic performance. JAMA Pediatr. 2017;2:171(1).Google Scholar
  116. 116.
    Grevelink JM, White VR, Bonoan R, Denman WT. Pulsed laser treatment in children and the use of anesthesia. J Am Acad Dermatol. 1997;37:75–81.CrossRefPubMedGoogle Scholar
  117. 117.
    Cunningham BB, Gigler V, Wang K, Eichenfield LF, Friedlander SF, et al. General anesthesia for pediatric dermatologic procedures: risk sand complications. Arch Dermatol. 2005;141(5):573–6.CrossRefPubMedGoogle Scholar
  118. 118.
    Terushkin V, Brauer J, Bernstein L, Geronemus R. Effect of general anesthesia on neurodevelopmental abnormalities in children undergoing treatment of vascular anomalies with laser surgery: a retrospective review. Dermatol Surg. 2017;43(4):534–40.CrossRefPubMedGoogle Scholar
  119. 119.
    Stier MF, Click SA, Hirsch RJ. Laser treatment of pediatric vascular lesions: port wine stains and hemangiomas. J Am Acad Dermatol. 2008;58(2):261–85.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of DermatologyNaval Medical Center Camp LejeuneCamp LejeuneUSA
  2. 2.Uniformed Services University of the Health SciencesBethesdaUSA
  3. 3.St. Luke’s University Health NetworkEastonUSA

Personalised recommendations